{"doc_id": "33663235", "type of study": "Therapy", "title": "", "abstract": "Effect of Empagliflozin as an Add-On Therapy on Decongestion and Renal Function in Patients With Diabetes Hospitalized for Acute Decompensated Heart Failure: A Prospective Randomized Controlled Study.\nEmpagliflozin reduces the risk of hospitalization for heart failure in patients with type 2 diabetes and cardiovascular disease.\nWe sought to elucidate the effect of empagliflozin as an add-on therapy on decongestion and renal function in patients with type 2 diabetes admitted for acute decompensated heart failure.\nThe study was terminated early due to COVID-19 pandemic.\nWe enrolled 59 consecutive patients with type 2 diabetes admitted for acute decompensated heart failure.\nPatients were randomly assigned to receive either empagliflozin add-on (n=30) or conventional glucose-lowering therapy (n=29).\nWe performed laboratory tests at baseline and 1, 2, 3, and 7 days after randomization.\nPercent change in plasma volume between admission and subsequent time points was calculated using the Strauss formula.\nThere were no significant baseline differences in left ventricular ejection fraction and serum NT-proBNP (N-terminal pro-B-type natriuretic peptide), hematocrit, or serum creatinine levels between the 2 groups.\nSeven days after randomization, NT-proBNP level was significantly lower in the empagliflozin group than in the conventional group (P=0.040), and hemoconcentration (\u22653% absolute increase in hematocrit) was more frequently observed in the empagliflozin group than in the conventional group (P=0.020).\nThe decrease in percent change in plasma volume between baseline and subsequent time points was significantly larger in the empagliflozin group than in the conventional group 7 days after randomization (P=0.017).\nThe incidence of worsening renal function (an increase in serum creatinine \u22650.3 mg/dL) did not significantly differ between the 2 groups.\nIn this exploratory analysis, empagliflozin achieved effective decongestion without an increased risk of worsening renal function as an add-on therapy in patients with type 2 diabetes with acute decompensated heart failure.\nRegistration: URL: https://www.umin.ac.jp/ctr/index.htm; Unique identifier: UMIN000026315.\n", "Evidence Map": {"Enrollment": [{"term": "Diabetes Hospitalized", "negation": "affirmed", "UMLS": {}, "start": 97, "end": 118}, {"term": "Acute Decompensated Heart Failure", "negation": "affirmed", "UMLS": {}, "start": 123, "end": 156}, {"term": "type 2 diabetes", "negation": "affirmed", "UMLS": {}, "start": 85, "end": 100}, {"term": "cardiovascular disease", "negation": "affirmed", "UMLS": {}, "start": 105, "end": 127}, {"term": "type 2 diabetes", "negation": "affirmed", "UMLS": {}, "start": 124, "end": 139}, {"term": "admitted", "negation": "affirmed", "UMLS": {}, "start": 140, "end": 148}, {"term": "acute decompensated heart failure", "negation": "affirmed", "UMLS": {}, "start": 153, "end": 186}, {"term": "type 2 diabetes admitted", "negation": "affirmed", "UMLS": {}, "start": 41, "end": 65}, {"term": "acute decompensated heart failure", "negation": "affirmed", "UMLS": {}, "start": 70, "end": 103}, {"term": "type 2 diabetes", "negation": "negated", "UMLS": {}, "start": 169, "end": 184}, {"term": "acute decompensated heart", "negation": "negated", "UMLS": {}, "start": 190, "end": 215}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Effect of Empagliflozin as an Add-On Therapy on Decongestion and Renal Function in Patients With Diabetes Hospitalized for Acute Decompensated Heart Failure : A Prospective Randomized Controlled Study .", "Evidence Elements": {"Participant": [{"term": "Diabetes Hospitalized", "negation": "affirmed", "UMLS": {}, "start": 97, "end": 118}, {"term": "Acute Decompensated Heart Failure", "negation": "affirmed", "UMLS": {}, "start": 123, "end": 156}], "Intervention": [{"term": "Empagliflozin", "negation": "affirmed", "UMLS": {}, "start": 10, "end": 23}], "Outcome": [{"term": "Decongestion", "negation": "affirmed", "UMLS": {}, "start": 48, "end": 60}, {"term": "Renal Function", "negation": "affirmed", "UMLS": {}, "start": 65, "end": 79}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "Empagliflozin reduces the risk of hospitalization for heart failure in patients with type 2 diabetes and cardiovascular disease .", "Evidence Elements": {"Participant": [{"term": "type 2 diabetes", "negation": "affirmed", "UMLS": {}, "start": 85, "end": 100}, {"term": "cardiovascular disease", "negation": "affirmed", "UMLS": {}, "start": 105, "end": 127}], "Intervention": [{"term": "Empagliflozin", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 13}], "Outcome": [{"term": "risk of hospitalization for heart failure", "negation": "affirmed", "UMLS": {}, "start": 26, "end": 67}], "Observation": [{"term": "reduces", "negation": "affirmed", "UMLS": {}, "start": 14, "end": 21}], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "We sought to elucidate the effect of empagliflozin as an add-on therapy on decongestion and renal function in patients with type 2 diabetes admitted for acute decompensated heart failure .", "Evidence Elements": {"Participant": [{"term": "type 2 diabetes", "negation": "affirmed", "UMLS": {}, "start": 124, "end": 139}, {"term": "admitted", "negation": "affirmed", "UMLS": {}, "start": 140, "end": 148}, {"term": "acute decompensated heart failure", "negation": "affirmed", "UMLS": {}, "start": 153, "end": 186}], "Intervention": [{"term": "empagliflozin", "negation": "affirmed", "UMLS": {}, "start": 37, "end": 50}], "Outcome": [{"term": "decongestion", "negation": "affirmed", "UMLS": {}, "start": 75, "end": 87}, {"term": "renal function", "negation": "affirmed", "UMLS": {}, "start": 92, "end": 106}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "The study was terminated early due to COVID-19 pandemic .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "We enrolled 59 consecutive patients with type 2 diabetes admitted for acute decompensated heart failure .", "Evidence Elements": {"Participant": [{"term": "type 2 diabetes admitted", "negation": "affirmed", "UMLS": {}, "start": 41, "end": 65}, {"term": "acute decompensated heart failure", "negation": "affirmed", "UMLS": {}, "start": 70, "end": 103}], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Patients were randomly assigned to receive either empagliflozin add-on ( n = 30 ) or conventional glucose-lowering therapy ( n = 29 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "empagliflozin add-on", "negation": "affirmed", "UMLS": {}, "start": 50, "end": 70}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "We performed laboratory tests at baseline and 1 , 2 , 3 , and 7 days after randomization .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "laboratory tests", "negation": "affirmed", "UMLS": {}, "start": 13, "end": 29}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Percent change in plasma volume between admission and subsequent time points was calculated using the Strauss formula .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "Percent change in plasma volume between admission and subsequent time points", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 76}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "There were no significant baseline differences in left ventricular ejection fraction and serum NT-proBNP ( N-terminal pro-B-type natriuretic peptide ) , hematocrit , or serum creatinine levels between the 2 groups .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "left ventricular ejection fraction", "negation": "negated", "UMLS": {}, "start": 50, "end": 84}, {"term": "serum NT-proBNP ( N-terminal pro-B-type natriuretic peptide )", "negation": "affirmed", "UMLS": {}, "start": 89, "end": 150}, {"term": "hematocrit", "negation": "negated", "UMLS": {}, "start": 153, "end": 163}, {"term": "serum creatinine levels", "negation": "negated", "UMLS": {}, "start": 169, "end": 192}], "Observation": [{"term": "significant baseline differences", "negation": "affirmed", "UMLS": {}, "start": 14, "end": 46}], "Count": []}, "Evidence Propositions": [{"Intervention": [], "Observation": "significant baseline differences", "Outcome": "left ventricular ejection fraction", "Count": ""}, {"Intervention": [], "Observation": "significant baseline differences", "Outcome": "serum NT-proBNP ( N-terminal pro-B-type natriuretic peptide )", "Count": ""}, {"Intervention": [], "Observation": "significant baseline differences", "Outcome": "hematocrit", "Count": ""}, {"Intervention": [], "Observation": "significant baseline differences", "Outcome": "serum creatinine levels", "Count": ""}]}, {"Section": "RESULTS", "Text": "Seven days after randomization , NT-proBNP level was significantly lower in the empagliflozin group than in the conventional group ( P = 0.040 ) , and hemoconcentration ( \u22653 % absolute increase in hematocrit ) was more frequently observed in the empagliflozin group than in the conventional group ( P = 0.020 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "empagliflozin", "negation": "affirmed", "UMLS": {}, "start": 80, "end": 93}, {"term": "conventional", "negation": "affirmed", "UMLS": {}, "start": 112, "end": 124}], "Outcome": [{"term": "NT-proBNP level", "negation": "affirmed", "UMLS": {}, "start": 33, "end": 48}, {"term": "hemoconcentration", "negation": "affirmed", "UMLS": {}, "start": 151, "end": 168}, {"term": "\u22653 % absolute increase in hematocrit", "negation": "affirmed", "UMLS": {}, "start": 171, "end": 207}], "Observation": [{"term": "significantly lower", "negation": "affirmed", "UMLS": {}, "start": 53, "end": 72}, {"term": "more frequently", "negation": "affirmed", "UMLS": {}, "start": 214, "end": 229}], "Count": []}, "Evidence Propositions": [{"Intervention": ["empagliflozin", "conventional"], "Observation": "significantly lower", "Outcome": "NT-proBNP level", "Count": ""}, {"Intervention": ["conventional"], "Observation": "more frequently", "Outcome": "hemoconcentration", "Count": ""}, {"Intervention": ["conventional"], "Observation": "more frequently", "Outcome": "\u22653 % absolute increase in hematocrit", "Count": ""}]}, {"Section": "RESULTS", "Text": "The decrease in percent change in plasma volume between baseline and subsequent time points was significantly larger in the empagliflozin group than in the conventional group 7 days after randomization ( P = 0.017 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "empagliflozin", "negation": "affirmed", "UMLS": {}, "start": 124, "end": 137}, {"term": "conventional", "negation": "affirmed", "UMLS": {}, "start": 156, "end": 168}], "Outcome": [{"term": "decrease in percent change in plasma volume between baseline and subsequent time points", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 91}], "Observation": [{"term": "significantly larger", "negation": "affirmed", "UMLS": {}, "start": 96, "end": 116}], "Count": []}, "Evidence Propositions": [{"Intervention": ["empagliflozin", "conventional"], "Observation": "significantly larger", "Outcome": "decrease in percent change in plasma volume between baseline and subsequent time points", "Count": ""}]}, {"Section": "RESULTS", "Text": "The incidence of worsening renal function ( an increase in serum creatinine \u22650.3 mg / dL ) did not significantly differ between the 2 groups .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "between the", "negation": "negated", "UMLS": {}, "start": 120, "end": 131}], "Outcome": [{"term": "incidence of worsening renal function", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 41}], "Observation": [{"term": "significantly differ", "negation": "negated", "UMLS": {}, "start": 99, "end": 119}], "Count": []}, "Evidence Propositions": []}, {"Section": "CONCLUSIONS", "Text": "In this exploratory analysis , empagliflozin achieved effective decongestion without an increased risk of worsening renal function as an add-on therapy in patients with type 2 diabetes with acute decompensated heart failure .", "Evidence Elements": {"Participant": [{"term": "type 2 diabetes", "negation": "negated", "UMLS": {}, "start": 169, "end": 184}, {"term": "acute decompensated heart", "negation": "negated", "UMLS": {}, "start": 190, "end": 215}], "Intervention": [{"term": "empagliflozin", "negation": "affirmed", "UMLS": {}, "start": 31, "end": 44}], "Outcome": [{"term": "decongestion", "negation": "affirmed", "UMLS": {}, "start": 64, "end": 76}, {"term": "risk of worsening renal function", "negation": "negated", "UMLS": {}, "start": 98, "end": 130}], "Observation": [{"term": "effective", "negation": "affirmed", "UMLS": {}, "start": 54, "end": 63}, {"term": "increased", "negation": "negated", "UMLS": {}, "start": 88, "end": 97}], "Count": []}, "Evidence Propositions": []}, {"Section": "CONCLUSIONS", "Text": "Registration : URL : https:/ / www . umin.ac.jp / ctr / index .htm ; Unique identifier : UMIN000026315 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}